PDF(Sci-hub)
Abstract：
UNASSIGNED: Tinnitus is a common and distressing otologic symptom, with various probable pathophysiologic mechanisms, such as an imbalance between excitatory and inhibitory mechanisms. Acamprosate, generally used to treat alcoholism, is a glutaminergic antagonist and GABA agonist suggested for treating tinnitus. Thus, we aimed to evaluate the efficacy and safety of acamprosate in the treatment of tinnitus.
UNASSIGNED: The current randomized-controlled trial study included 20 subjects with chronic tinnitus. After performing psycho-acoustic, psychometric and electrophysiological evaluations, all studied tinnitus subjects were randomly divided into two groups of acamprosate and placebo. The first group received oral acamprosate (two tablets of 333 mg/d, three times a day), whereas the second group was given placebo treatment (two tablets, three times a day). After the first 30 days, all evaluations were repeated for the studied groups just in the same manner before the study. Subsequently, the final results of each evaluation were compared together with the baseline values.
UNASSIGNED: Nine studied subjects randomly received acamprosate, whereas eleven others received a placebo. There was no significant improvement in the psycho-acoustic tests, except a decrease was observed in the pitch match of tinnitus (P = .039). For those subjects who were receiving acamprosate, a significant reduction was observed in tinnitus handicap inventory (P = .006), tinnitus questionnaire scores (P = .007), and the visual analog scores (P = .007) compared to the placebo group. There was a significant reduction in Action Potential latency (P = .048) as well as an increase in the amplitude of distortion product otoacoustic emissions at 4 kHz (P = .048).
UNASSIGNED: The study results indicated a subjective relief of tinnitus as well as some degree of the electrophysiological improvement at the level of the cochlear and the distal portion of the auditory nerve among the subjects who received the acamprosate.
UNASSIGNED: IRCT2013121115751N1.
UNASSIGNED: The current randomized-controlled trial study included 20 subjects with chronic tinnitus. After performing psycho-acoustic, psychometric and electrophysiological evaluations, all studied tinnitus subjects were randomly divided into two groups of acamprosate and placebo. The first group received oral acamprosate (two tablets of 333 mg/d, three times a day), whereas the second group was given placebo treatment (two tablets, three times a day). After the first 30 days, all evaluations were repeated for the studied groups just in the same manner before the study. Subsequently, the final results of each evaluation were compared together with the baseline values.
UNASSIGNED: Nine studied subjects randomly received acamprosate, whereas eleven others received a placebo. There was no significant improvement in the psycho-acoustic tests, except a decrease was observed in the pitch match of tinnitus (P = .039). For those subjects who were receiving acamprosate, a significant reduction was observed in tinnitus handicap inventory (P = .006), tinnitus questionnaire scores (P = .007), and the visual analog scores (P = .007) compared to the placebo group. There was a significant reduction in Action Potential latency (P = .048) as well as an increase in the amplitude of distortion product otoacoustic emissions at 4 kHz (P = .048).
UNASSIGNED: The study results indicated a subjective relief of tinnitus as well as some degree of the electrophysiological improvement at the level of the cochlear and the distal portion of the auditory nerve among the subjects who received the acamprosate.
UNASSIGNED: IRCT2013121115751N1.
摘要：
■耳鸣是一种常见且令人痛苦的耳科症状，具有各种可能的病理生理机制，例如兴奋和抑制机制之间的不平衡。阿坎酸,一般用于治疗酒精中毒，是建议用于治疗耳鸣的谷氨酸能拮抗剂和GABA激动剂。因此，我们旨在评估阿坎酸治疗耳鸣的疗效和安全性。
■目前的随机对照试验研究包括20名慢性耳鸣受试者。在表演了心理声学之后，心理测量和电生理评估，所有研究的耳鸣受试者被随机分为阿坎酸和安慰剂两组。第一组口服阿坎酸（两片333mg/d，一天三次)，而第二组给予安慰剂治疗(两片，一天三次)。前30天之后,对研究组的所有评估在研究前都以相同的方式重复进行.随后，将每次评估的最终结果与基线值进行比较.
■9名研究对象随机接受阿坎酸，而其他11人接受了安慰剂。心理声学测试没有明显改善，除了在耳鸣的音高匹配中观察到下降（P=.039）。对于那些接受阿坎酸治疗的受试者，观察到耳鸣障碍库存显着减少（P=.006），耳鸣问卷得分(P=.007)，与安慰剂组相比，视觉模拟评分（P=0.007）。动作电位潜伏期显着减少（P=.048），并且在4kHz时失真产物耳声发射的幅度增加（P=.048）。
■研究结果表明，在接受阿坎酸治疗的受试者中，耳鸣的主观缓解以及耳蜗水平和听觉神经远端部分的电生理改善。
■IRCT2013121115751N1。
■目前的随机对照试验研究包括20名慢性耳鸣受试者。在表演了心理声学之后，心理测量和电生理评估，所有研究的耳鸣受试者被随机分为阿坎酸和安慰剂两组。第一组口服阿坎酸（两片333mg/d，一天三次)，而第二组给予安慰剂治疗(两片，一天三次)。前30天之后,对研究组的所有评估在研究前都以相同的方式重复进行.随后，将每次评估的最终结果与基线值进行比较.
■9名研究对象随机接受阿坎酸，而其他11人接受了安慰剂。心理声学测试没有明显改善，除了在耳鸣的音高匹配中观察到下降（P=.039）。对于那些接受阿坎酸治疗的受试者，观察到耳鸣障碍库存显着减少（P=.006），耳鸣问卷得分(P=.007)，与安慰剂组相比，视觉模拟评分（P=0.007）。动作电位潜伏期显着减少（P=.048），并且在4kHz时失真产物耳声发射的幅度增加（P=.048）。
■研究结果表明，在接受阿坎酸治疗的受试者中，耳鸣的主观缓解以及耳蜗水平和听觉神经远端部分的电生理改善。
■IRCT2013121115751N1。
